SpringWorks Therapeutics, Inc. SWTX NASDAQ

SpringWorks Therapeutics, Inc. (SWTX) reported total assets of $587.28M and total liabilities of $106.17M for fiscal year 2024, resulting in total equity of $481.1M.

The company held $307.99M in cash and short-term investments. Total debt stood at $7.91M, with net debt of $-61.84M. The Debt-to-Equity (D/E) ratio was 0.02 (conservative).

Current ratio is 3.81, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.02, current ratio of 3.81 — balance sheet is strong
• MOAT (70/100) — Total assets $587.28M and equity $481.1M support the company's competitive scale
• VALUE (90/100) — Debt-to-Equity 0.02 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 57/100 with 4/7 criteria passed.

RVMD

Revolution Medicines, Inc.

$147.01

+7.86%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

CERE

Cerevel Therapeutics Holdings, Inc.

$44.96

+0.74%

KYMR

Kymera Therapeutics, Inc.

$89.87

+1.51%

APLS

Apellis Pharmaceuticals, Inc.

$40.85

+0.02%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

MRTX

Mirati Therapeutics, Inc.

$58.70

-0.17%

RLAY

Relay Therapeutics, Inc.

$14.75

-3.34%